Bevacizumab vs bevacizumab-awwb

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Non-Small Cell Lung Cancer

Shared mechanism: VEGF-A · full Non-Small Cell Lung Cancer pipeline

Bevacizumab

Marketed by Roche

Approved in Non-Small Cell Lung Cancermonoclonal antibody
Partial signal

NCT00806923 · Phase 3 · completed

This is a large, randomized, placebo-controlled trial with a clinical primary endpoint (progression-free survival). Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.

Next expected readout: November 2026 · NCT04958811 (registry estimate)

Reported efficacy

Progression-free survival (Event driven): Progression-free survival: HR 0.75 (95% CI 0.64-0.87; P=0.0003) for bevacizumab 7.5 mg/kg + cisplatin/gemcitabine vs placebo + cisplatin/gemcitabine, and HR 0.85 (95% CI 0.73-1.00; P=0.0456) for bevacizumab 15 mg/kg vs placebo (met)

Result source: NCT00806923

bevacizumab-awwb · MVASI

Marketed by Amgen and partners

Approved in Non-Small Cell Lung Cancermonoclonal antibody
Reliable signal

NCT01966003 · Phase 3 · completed

This randomized, quadruple-blind, active-controlled Phase 3 trial in 642 patients with advanced non-small cell lung cancer compared the biosimilar bevacizumab-awwb with reference bevacizumab, both added to chemotherapy. Objective response rates were closely matched (39.0% vs 41.7%), and the prespecified statistical test showed the two products were clinically equivalent.

Reported efficacy

Percentage of Participants With an Objective Response (Disease assessments were performed at weeks 1, 7, 13, 19, and approximately every 9 weeks thereafter. The mean actual follow-up time from randomization was 4.7 and 5.0 months for ABP 215 and bevacizumab, respectively.): Objective response rate (central independent blinded review, RECIST v1.1), ABP 215 (bevacizumab-awwb, n=328) vs bevacizumab (n=314): 39.0% vs 41.7%; risk ratio 0.93 (2-sided 90% CI 0.80 to 1.09), inside the prespecified equivalence margin of 0.67 to 1.5 (CT.gov posted results). (met)

Result source: NCT01966003

Results for Non-Small Cell Lung Cancer

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointBevacizumabbevacizumab-awwb
PFS, median4.8 vs 3.7+1.1 vs placebon 370NCT00257608
17 other results
6.6 vs 7.9vs Bevacizumabn 328NCT01966003
OS, median9.3 vs 9.2+0.1 vs placebon 319NCT00130728
20 other results
—Not reported
ORR47.6% vs 42.8%vs Bevacizumab (Avastin)wk 24 · n 379NCT02754882
9 other results
  • 40.3% vs 44.6% wk 18 · n 315 · Phase 3 · primary NCT03296163
  • 44.3% vs 46.4% wk 18 · n 221 · Phase 3 · primary NCT02954172
  • 51.6% vs 53.7% n 364 · Phase 3 · primary NCT02810457
  • 12.6% vs 6.2% n 301 · Phase 3 · secondary NCT00130728
  • 47.8% vs 51% wk 19 · n 364 · Phase 3 · secondary NCT02810457
  • 8.6% vs 6.3% n 245 · Phase 3 · secondary NCT01351415
  • 34.1% vs 33% n 472 · Phase 3 · secondary NCT00762034
  • 18.2% n 22 · Phase 2 · primary NCT04426825
  • 17.4% n 23 · Phase 2 · secondary NCT04426825
39% vs 41.7%vs Bevacizumabn 328NCT01966003
Duration of response, median9.7 vs 8.4+1.3 vs placebon 38NCT00130728
4 other results
5.8 vs 5.6vs Bevacizumabn 128NCT01966003

PFS, median

Bevacizumab
4.8 vs 3.7+1.1 vs placebon 370NCT00257608
17 other results
bevacizumab-awwb
6.6 vs 7.9vs Bevacizumabn 328NCT01966003

OS, median

Bevacizumab
9.3 vs 9.2+0.1 vs placebon 319NCT00130728
20 other results
bevacizumab-awwb
—Not reported

ORR

Bevacizumab
47.6% vs 42.8%vs Bevacizumab (Avastin)wk 24 · n 379NCT02754882
9 other results
  • 40.3% vs 44.6% wk 18 · n 315 · Phase 3 · primary NCT03296163
  • 44.3% vs 46.4% wk 18 · n 221 · Phase 3 · primary NCT02954172
  • 51.6% vs 53.7% n 364 · Phase 3 · primary NCT02810457
  • 12.6% vs 6.2% n 301 · Phase 3 · secondary NCT00130728
  • 47.8% vs 51% wk 19 · n 364 · Phase 3 · secondary NCT02810457
  • 8.6% vs 6.3% n 245 · Phase 3 · secondary NCT01351415
  • 34.1% vs 33% n 472 · Phase 3 · secondary NCT00762034
  • 18.2% n 22 · Phase 2 · primary NCT04426825
  • 17.4% n 23 · Phase 2 · secondary NCT04426825
bevacizumab-awwb
39% vs 41.7%vs Bevacizumabn 328NCT01966003

Duration of response, median

Bevacizumab
9.7 vs 8.4+1.3 vs placebon 38NCT00130728
4 other results
bevacizumab-awwb
5.8 vs 5.6vs Bevacizumabn 128NCT01966003
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Bevacizumab: 4 of 4 rows · bevacizumab-awwb: 3 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricBevacizumab
Rows use multiple source trials
bevacizumab-awwb
Dropout rate
99.4%a
NCT00451906 · Phase 4 · registry result, not featured evidence · combination
show 31 more results
64.2%
NCT00324805 · Phase 3 · registry result, not featured evidence · combination
89.8%
NCT02810457 · Phase 3 · registry result, not featured evidence
—Arm A (Atezo+CP)
NCT02366143 · Phase 3 · registry result, not featured evidence · combination · Non-Small Cell Lung Cancer · phase 3
—Arm B (Atezo+Bev+CP)
NCT02366143 · Phase 3 · registry result, not featured evidence · combination · Non-Small Cell Lung Cancer · phase 3
34.3%
NCT03296163 · Phase 3 · registry result, not featured evidence
82.1%
NCT00130728 · Phase 3 · registry result, not featured evidence · combination
1.3%
NCT02954172 · Phase 3 · registry result, not featured evidence · combination
90.8%
NCT02754882 · Phase 3 · registry result, not featured evidence
n/a: no completion milestone
NCT01351415 · Phase 3 · registry result, not featured evidence · combination
37.7%
NCT00762034 · Phase 3 · registry result, not featured evidence · combination
—
NCT00257608 · Phase 3 · registry result, not featured evidence · combination
31.9%Bevacizumab + Pemetrexed
NCT00976456 · Phase 3 · registry result, not featured evidence · combination
27.9%Bevacizumab + Pemetrexed + Carbopl
NCT00976456 · Phase 3 · registry result, not featured evidence · combination
0%
NCT01661790 · Phase 3 · registry result, not featured evidence · combination
—Bevacizumab +Pemetrexed Maintenanc
NCT00961415 · Phase 3 · registry result, not featured evidence · combination
—Maintenance Treatment Arm A
NCT00961415 · Phase 3 · registry result, not featured evidence
—Maintenance Treatment Arm B
NCT00961415 · Phase 3 · registry result, not featured evidence · combination
64.9%Osimertinib Alone
NCT03133546 · Phase 2 · registry result, not featured evidence · monotherapy
65.4%Osimertinib Plus Bevacizumab
NCT03133546 · Phase 2 · registry result, not featured evidence · combination
n/a: no completion milestone
NCT04426825 · Phase 2 · registry result, not featured evidence · combination
0%Arm A (Erlotinib Hydrochloride)
NCT01532089 · Phase 2 · registry result, not featured evidence
0%Arm B (Erlotinib Hydrochloride, Be
NCT01532089 · Phase 2 · registry result, not featured evidence · combination
100%10 mg/kg + mFOLFOX6 ± Bevacizumab
NCT01327612 · Phase 2 · registry result, not featured evidence · combination
100%5 mg/kg
NCT01327612 · Phase 2 · registry result, not featured evidence
100%3 mg/kg
NCT01327612 · Phase 2 · registry result, not featured evidence
100%2 mg/kg + mFOLFOX6 + Bevacizumab
NCT01327612 · Phase 2 · registry result, not featured evidence · combination
100%0.45 mg/kg
NCT01327612 · Phase 2 · registry result, not featured evidence
—
NCT00828009 · Phase 2 · registry result, not featured evidence
—
NCT00271505 · Phase 2 · registry result, not featured evidence · combination
0%
NCT00227019 · Phase 2 · registry result, not featured evidence · combination
7.7%
NCT00655850 · Phase 2 · registry result, not featured evidence · combination
82.3%
NCT01966003 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
Discontinued due to AEs
22.9%a
NCT00451906 · Phase 4 · registry result, not featured evidence · combination
show 31 more results
27%
NCT00324805 · Phase 3 · registry result, not featured evidence · combination
10.2%
NCT02810457 · Phase 3 · registry result, not featured evidence
—Arm A (Atezo+CP)
NCT02366143 · Phase 3 · registry result, not featured evidence · combination · Non-Small Cell Lung Cancer · phase 3
—Arm B (Atezo+Bev+CP)
NCT02366143 · Phase 3 · registry result, not featured evidence · combination · Non-Small Cell Lung Cancer · phase 3
—
NCT03296163 · Phase 3 · registry result, not featured evidence
—
NCT00130728 · Phase 3 · registry result, not featured evidence · combination
—
NCT02954172 · Phase 3 · registry result, not featured evidence · combination
—
NCT02754882 · Phase 3 · registry result, not featured evidence
—
NCT01351415 · Phase 3 · registry result, not featured evidence · combination
5.7%
NCT00762034 · Phase 3 · registry result, not featured evidence · combination
—
NCT00257608 · Phase 3 · registry result, not featured evidence · combination
12.6%Bevacizumab + Pemetrexed
NCT00976456 · Phase 3 · registry result, not featured evidence · combination
16.2%Bevacizumab + Pemetrexed + Carbopl
NCT00976456 · Phase 3 · registry result, not featured evidence · combination
—
NCT01661790 · Phase 3 · registry result, not featured evidence · combination
—Bevacizumab +Pemetrexed Maintenanc
NCT00961415 · Phase 3 · registry result, not featured evidence · combination
—Maintenance Treatment Arm A
NCT00961415 · Phase 3 · registry result, not featured evidence
—Maintenance Treatment Arm B
NCT00961415 · Phase 3 · registry result, not featured evidence · combination
—Osimertinib Alone
NCT03133546 · Phase 2 · registry result, not featured evidence · monotherapy
—Osimertinib Plus Bevacizumab
NCT03133546 · Phase 2 · registry result, not featured evidence · combination
—
NCT04426825 · Phase 2 · registry result, not featured evidence · combination
—Arm A (Erlotinib Hydrochloride)
NCT01532089 · Phase 2 · registry result, not featured evidence
—Arm B (Erlotinib Hydrochloride, Be
NCT01532089 · Phase 2 · registry result, not featured evidence · combination
—10 mg/kg + mFOLFOX6 ± Bevacizumab
NCT01327612 · Phase 2 · registry result, not featured evidence · combination
—5 mg/kg
NCT01327612 · Phase 2 · registry result, not featured evidence
—3 mg/kg
NCT01327612 · Phase 2 · registry result, not featured evidence
—2 mg/kg + mFOLFOX6 + Bevacizumab
NCT01327612 · Phase 2 · registry result, not featured evidence · combination
—0.45 mg/kg
NCT01327612 · Phase 2 · registry result, not featured evidence
—
NCT00828009 · Phase 2 · registry result, not featured evidence
—
NCT00271505 · Phase 2 · registry result, not featured evidence · combination
—
NCT00227019 · Phase 2 · registry result, not featured evidence · combination
—
NCT00655850 · Phase 2 · registry result, not featured evidence · combination
—
NCT01966003 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
Serious AEs
37.7%a
NCT00451906 · Phase 4 · registry result, not featured evidence · combination
show 31 more results
76.6%
NCT00324805 · Phase 3 · registry result, not featured evidence · combination
25.1%
NCT02810457 · Phase 3 · registry result, not featured evidence
42.5%Arm A (Atezo+CP)
NCT02366143 · Phase 3 · registry result, not featured evidence · combination · Non-Small Cell Lung Cancer · phase 3
48.3%Arm B (Atezo+Bev+CP)
NCT02366143 · Phase 3 · registry result, not featured evidence · combination · Non-Small Cell Lung Cancer · phase 3
18.6%
NCT03296163 · Phase 3 · registry result, not featured evidence
46.6%
NCT00130728 · Phase 3 · registry result, not featured evidence · combination
33.5%
NCT02954172 · Phase 3 · registry result, not featured evidence · combination
19.8%
NCT02754882 · Phase 3 · registry result, not featured evidence
51.9%
NCT01351415 · Phase 3 · registry result, not featured evidence · combination
42.5%
NCT00762034 · Phase 3 · registry result, not featured evidence · combination
23.4%
NCT00257608 · Phase 3 · registry result, not featured evidence · combination
6.7%Bevacizumab + Pemetrexed
NCT00976456 · Phase 3 · registry result, not featured evidence · combination
5.2%Bevacizumab + Pemetrexed + Carbopl
NCT00976456 · Phase 3 · registry result, not featured evidence · combination
0%
NCT01661790 · Phase 3 · registry result, not featured evidence · combination
—Bevacizumab +Pemetrexed Maintenanc
NCT00961415 · Phase 3 · registry result, not featured evidence · combination
21.7%Maintenance Treatment Arm A
NCT00961415 · Phase 3 · registry result, not featured evidence
33.6%Maintenance Treatment Arm B
NCT00961415 · Phase 3 · registry result, not featured evidence · combination
35.1%Osimertinib Alone
NCT03133546 · Phase 2 · registry result, not featured evidence · monotherapy
43.4%Osimertinib Plus Bevacizumab
NCT03133546 · Phase 2 · registry result, not featured evidence · combination
17.4%
NCT04426825 · Phase 2 · registry result, not featured evidence · combination
26.7%Arm A (Erlotinib Hydrochloride)
NCT01532089 · Phase 2 · registry result, not featured evidence
39.5%Arm B (Erlotinib Hydrochloride, Be
NCT01532089 · Phase 2 · registry result, not featured evidence · combination
100%10 mg/kg + mFOLFOX6 ± Bevacizumab
NCT01327612 · Phase 2 · registry result, not featured evidence · combination
0%5 mg/kg
NCT01327612 · Phase 2 · registry result, not featured evidence
100%3 mg/kg
NCT01327612 · Phase 2 · registry result, not featured evidence
50%2 mg/kg + mFOLFOX6 + Bevacizumab
NCT01327612 · Phase 2 · registry result, not featured evidence · combination
0%0.45 mg/kg
NCT01327612 · Phase 2 · registry result, not featured evidence
33.3%
NCT00828009 · Phase 2 · registry result, not featured evidence
32.5%
NCT00271505 · Phase 2 · registry result, not featured evidence · combination
50%
NCT00227019 · Phase 2 · registry result, not featured evidence · combination
69.4%
NCT00655850 · Phase 2 · registry result, not featured evidence · combination
26.2%
NCT01966003 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
Most frequent reported AEs
a
fatigue 40.4%
nausea 37.4%
haemoglobin decreased 35.6%
NCT00451906 · Phase 4 · registry result, not featured evidence · combination
show 30 more results
creatinine increased 33.6%
neutrophil count decreased 32.1%
anemia 24.9%
NCT00324805 · Phase 3 · registry result, not featured evidence · combination
alopecia 42.5%
neutropenia 30.1%
anaemia 29%
NCT02810457 · Phase 3 · registry result, not featured evidence
alopecia 45%
anaemia 36.5%
nausea 32.5%
NCT02366143 · Phase 3 · registry result, not featured evidence · combination · Non-Small Cell Lung Cancer · phase 3
alopecia 47.8%
nausea 37.9%
fatigue 34.9%
NCT02366143 · Phase 3 · registry result, not featured evidence · combination · Non-Small Cell Lung Cancer · phase 3
alopecia 49.8%
anemia 32.5%
nausea 15.1%
NCT03296163 · Phase 3 · registry result, not featured evidence
diarrhoea 64.9% (placebo 51.8%)
rash 61.7% (placebo 58.8%)
fatigue 46.6% (placebo 39.6%)
NCT00130728 · Phase 3 · registry result, not featured evidence · combination
white blood cell count decreased 71.9%
neutrophil count decreased 70.5%
platelet count decreased 50.4%
NCT02954172 · Phase 3 · registry result, not featured evidence · combination
alopecia 48.7%
anaemia 23%
nausea 19.6%
NCT02754882 · Phase 3 · registry result, not featured evidence
diarrhoea 37%
nausea 34.6%
decreased appetite 34.2%
NCT01351415 · Phase 3 · registry result, not featured evidence · combination
fatigue 60.6%
nausea 53.4%
constipation 41%
NCT00762034 · Phase 3 · registry result, not featured evidence · combination
rash 55.4% (placebo 18.8%)
diarrhoea 51.1% (placebo 19.6%)
fatigue 34.2% (placebo 24.8%)
NCT00257608 · Phase 3 · registry result, not featured evidence · combination
anaemia 51.3%
NCT00976456 · Phase 3 · registry result, not featured evidence · combination
anaemia 72.4%
NCT00976456 · Phase 3 · registry result, not featured evidence · combination
leucocytopenia 66.7%
NCT01661790 · Phase 3 · registry result, not featured evidence · combination
nausea 60.8%
hypertension 35.8%
asthenia 35%
NCT00961415 · Phase 3 · registry result, not featured evidence
nausea 61.6%
hypertension 44%
fatigue 32%
NCT00961415 · Phase 3 · registry result, not featured evidence · combination
diarrhea 49.4%
fatigue 37.7%
cough 36.4%
NCT03133546 · Phase 2 · registry result, not featured evidence · monotherapy
diarrhea 53.9%
proteinuria 48.7%
fatigue 43.4%
NCT03133546 · Phase 2 · registry result, not featured evidence · combination
proteinuria 30.4%
aspartate aminotransferase increased 26.1%
fatigue 26.1%
NCT04426825 · Phase 2 · registry result, not featured evidence · combination
rash acneiform 88.9%
diarrhea 82.2%
hypertension 51.1%
NCT01532089 · Phase 2 · registry result, not featured evidence
rash acneiform 97.7%
diarrhea 88.4%
hypertension 83.7%
NCT01532089 · Phase 2 · registry result, not featured evidence · combination
10 mg/kg + mFOLFOX6 ± Bevacizumab
abdominal pain 66.7%
amylase increased 66.7%
anaemia 66.7%
NCT01327612 · Phase 2 · registry result, not featured evidence · combination
5 mg/kg
back pain 100%
blood creatinine increased 100%
blood phosphorus increased 100%
NCT01327612 · Phase 2 · registry result, not featured evidence
3 mg/kg
hepatic enzyme increased 100%
hepatitis c 100%
oesophageal carcinoma 100%
NCT01327612 · Phase 2 · registry result, not featured evidence
2 mg/kg + mFOLFOX6 + Bevacizumab
diarrhoea 100%
fatigue 100%
neutropenia 100%
NCT01327612 · Phase 2 · registry result, not featured evidence · combination
0.45 mg/kg
chest x-ray abnormal 100%
cough 100%
herpes zoster 100%
NCT01327612 · Phase 2 · registry result, not featured evidence
fatigue 78.8%
anemia 54.5%
peripheral sensory neuropathy 51.5%
NCT00828009 · Phase 2 · registry result, not featured evidence
alopecia 62.5%
fatigue 52.5%
hyperglycemia 52.5%
NCT00271505 · Phase 2 · registry result, not featured evidence · combination
pain 75%
fatigue 68.8%
anorexia 50%
NCT00227019 · Phase 2 · registry result, not featured evidence · combination
fatigue: induction 88.9%
hypertension grade: end of induction 88.9%
anemia: induction 75%
NCT00655850 · Phase 2 · registry result, not featured evidence · combination
alopecia 43.2%
nausea 25.3%
anaemia 20.1%
NCT01966003 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3

Notes

  1. aPopulation comparability has not been reviewed for 30 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Bevacizumab

Overall Survival 14.6 months
time to event · months
No placebo or comparator arm
NCT00451906 · Phase 4 · registry result, not featured evidence · combination
show 11 more results
11.6 months @ 183wk
NCT00976456 · Phase 3 · registry result, not featured evidence · combination
14.4 months @ 183wk
NCT00976456 · Phase 3 · registry result, not featured evidence · combination
24 months
NCT03133546 · Phase 2 · registry result, not featured evidence · combination
24.3 months
NCT03133546 · Phase 2 · registry result, not featured evidence · monotherapy
14.06 months
NCT04426825 · Phase 2 · registry result, not featured evidence · combination
50.6 months
NCT01532089 · Phase 2 · registry result, not featured evidence
32.4 months
NCT01532089 · Phase 2 · registry result, not featured evidence · combination
42.7 months
NCT00828009 · Phase 2 · registry result, not featured evidence
16.5 months
NCT00271505 · Phase 2 · registry result, not featured evidence · combination
14.8 months
NCT00227019 · Phase 2 · registry result, not featured evidence · combination
25.5 months
NCT00655850 · Phase 2 · registry result, not featured evidence · combination
Time to Progression 7.8 months
time to event · months
No placebo or comparator arm
NCT00451906 · Phase 4 · registry result, not featured evidence · combination
Disease-free Survival 40.6 vs 42.9 Chemotherapy months
time to event · months
NCT00324805 · Phase 3 · registry result, not featured evidence · combination
Disease Control 87.6% (n=364) vs 87.5% (n=367) Avastin
absolute value · percentage points
NCT02810457 · Phase 3 · registry result, not featured evidence
PFS 8.3 vs 6.8 Bevacizumab+Paclitaxel+Carboplatin months
time to event · months
ITT Population
NCT02366143 · Phase 3 · registry result, not featured evidence · combination · Non-Small Cell Lung Cancer · phase 3
Overall Survival 19.8 vs 14.9 Bevacizumab+Paclitaxel+Carboplatin months
time to event · months
ITT Population
NCT02366143 · Phase 3 · registry result, not featured evidence · combination · Non-Small Cell Lung Cancer · phase 3
show 1 more result
19 vs 15 Bevacizumab+Paclitaxel+Carboplatin months
ITT Population
NCT02366143 · Phase 3 · registry result, not featured evidence · combination · Non-Small Cell Lung Cancer · phase 3
Duration of Response 9 vs 5.7 Bevacizumab+Paclitaxel+Carboplatin months
time to event · months
ITT-WT Population
NCT02366143 · Phase 3 · registry result, not featured evidence · combination · Non-Small Cell Lung Cancer · phase 3
ORR 49.3% (n=347) vs 48% (n=331) Bevacizumab+Paclitaxel+Carboplatin
responder rate · % of participants
ITT-WT Population
NCT02366143 · Phase 3 · registry result, not featured evidence · combination · Non-Small Cell Lung Cancer · phase 3
show 1 more result
63.5% (n=353) vs 48% (n=331) Bevacizumab+Paclitaxel+Carboplatin
ITT-WT Population
NCT02366143 · Phase 3 · registry result, not featured evidence · combination · Non-Small Cell Lung Cancer · phase 3
PFS 8.5 vs 7.9 Bevacizumab (Avastin) months
time to event · months
FAS
NCT02754882 · Phase 3 · registry result, not featured evidence
Overall Survival 14.9 vs 15.8 Bevacizumab (Avastin) months
time to event · months
FAS
NCT02754882 · Phase 3 · registry result, not featured evidence
Duration of Response 6.38 vs 6.79 Bevacizumab (Avastin) months
time to event · months
FAS
NCT02754882 · Phase 3 · registry result, not featured evidence
PFS2 5.45 vs 3.98 Standard of Care months
time to event · months
PFS 2
NCT01351415 · Phase 3 · registry result, not featured evidence · combination

+ 29 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Bevacizumab's landscape · bevacizumab-awwb's landscape